Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18080224rdf:typepubmed:Citationlld:pubmed
pubmed-article:18080224lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:18080224lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:18080224lifeskim:mentionsumls-concept:C0038317lld:lifeskim
pubmed-article:18080224lifeskim:mentionsumls-concept:C0009324lld:lifeskim
pubmed-article:18080224lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:18080224lifeskim:mentionsumls-concept:C0205269lld:lifeskim
pubmed-article:18080224lifeskim:mentionsumls-concept:C0205296lld:lifeskim
pubmed-article:18080224lifeskim:mentionsumls-concept:C0443252lld:lifeskim
pubmed-article:18080224pubmed:issue12lld:pubmed
pubmed-article:18080224pubmed:dateCreated2007-12-14lld:pubmed
pubmed-article:18080224pubmed:abstractTextIn some steroid refractory patients with active ulcerative colitis (UC), treatment with immunosuppressive agents, such as cyclosporin, azathioprine or 6-mercaptopurin is effective. However, there are patients who fail to respond to these treatment options or who cannot tolerate them. Application of natural interferon-beta (nIFN-beta) may offer an alternative. Following our positive results with nIFN-beta in a previously published open-labeled study, the present study was designed as an extension with the hypothesis that administration of higher dosage of nIFN-beta (1.0 vs. 0.5 MIU) could result in fewer relapse events.lld:pubmed
pubmed-article:18080224pubmed:languageenglld:pubmed
pubmed-article:18080224pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080224pubmed:citationSubsetIMlld:pubmed
pubmed-article:18080224pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080224pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080224pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080224pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080224pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18080224pubmed:statusMEDLINElld:pubmed
pubmed-article:18080224pubmed:monthDeclld:pubmed
pubmed-article:18080224pubmed:issn0044-2771lld:pubmed
pubmed-article:18080224pubmed:authorpubmed-author:SchulzMMlld:pubmed
pubmed-article:18080224pubmed:authorpubmed-author:MalecEElld:pubmed
pubmed-article:18080224pubmed:authorpubmed-author:MuschEElld:pubmed
pubmed-article:18080224pubmed:authorpubmed-author:AndusTTlld:pubmed
pubmed-article:18080224pubmed:authorpubmed-author:ChrissafidouA...lld:pubmed
pubmed-article:18080224pubmed:issnTypePrintlld:pubmed
pubmed-article:18080224pubmed:volume45lld:pubmed
pubmed-article:18080224pubmed:ownerNLMlld:pubmed
pubmed-article:18080224pubmed:authorsCompleteYlld:pubmed
pubmed-article:18080224pubmed:pagination1235-40lld:pubmed
pubmed-article:18080224pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:meshHeadingpubmed-meshheading:18080224...lld:pubmed
pubmed-article:18080224pubmed:year2007lld:pubmed
pubmed-article:18080224pubmed:articleTitleSuccessful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial.lld:pubmed
pubmed-article:18080224pubmed:affiliationDepartment of Internal Medicine, Marienhospital Bottrop, Germany. eugen.musch@mhb-bottrop.delld:pubmed
pubmed-article:18080224pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18080224pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:18080224pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18080224lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18080224lld:pubmed